EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent

Naseema Gangat iD, Azeem Elbeih, Nour Ghosoun, Kristen McCullough iD, Fnu Aperna, Isla M Johnson, Maymona Abdelmagid, Aref Al-Kali iD, Hassan B Alkhateeb, Kebede H Begna iD, Michelle Elliott iD, Abhishek Mangaonkar iD und 25 weitere

American Journal of Hematology · 2025-02 · 100 (2) · 260-271

DOI: 10.1002/ajh.27564 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 13.12.2024. Verfasst von Naseema Gangat und 36 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Leukemia, Myeloid, Acute, Sulfonamides. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with newly diagnosed acute myeloid leukemia (ND‐AML) derive variable survival benefit from venetoclax + hypomethylating agent (Ven‐HMA) therapy. The primary objective in the current study was to develop genetic risk models that are predictive of survival and are applicable at the time of diagnosis and after establishing treatment response. Among 400 ND‐AML patients treated with Ven‐HMA at the Mayo Clinic, 247 (62%) achieved complete remission with (CR) or without (CRi) count recovery. Multivariable analysis–derived hazard ratios (HR), including 1.8 for European LeukemiaNet (ELN) adverse karyotype, 4.7 for KMT2Ar , 1.7 for TP53 MUT , 2.6 for KRAS MUT , and 2.1 for IDH2 WT were applied to develop an HR‐weighted risk model: low, intermediate, and high; respective median survival censored for allogeneic stem cell transplant (ASCT) (3‐year survival) were “not reached” (67%), 19.1 (33%), and 7.1 months (0%). In patients achieving CR/CRi, adverse karyotype, KMT2Ar , KRAS MUT , IDH2 WT predicted inferior survival, allowing for a complementary response‐stratified risk model. The model was externally validated and was shown to be superior to the ELN 2024 risk model (AIC 179 vs. 195 and AUC 0.77 vs. 0.69). Survival was inferior with failure to achieve CR/CRi or not receiving ASCT; 3‐year survival for high‐risk with or without ASCT was 42% versus 0% ( p < 0.01); intermediate 72% versus 43% ( p = 0.06); and low‐risk 88% versus 78% ( p = 0.53). The Mayo genetic risk models offer pre‐treatment and response‐based prognostic tools for ND‐AML treated with Ven‐HMA. The current study underscores the prognostically indispensable role of achieving CR/CRi and ASCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bridged Bicyclo Compounds, HeterocyclicLeukemia, Myeloid, AcuteSulfonamidesHumansMiddle AgedFemaleAgedMaleAdultAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsYoung AdultDNA Methylation

Stichwörter der Autor:innen

karyotypemutationsremissionsurvivalvenetoclax

Substanzen

Bridged Bicyclo Compounds, HeterocyclicvenetoclaxSulfonamides

Autor:innen und Institutionen

  • Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Hematology, Mayo Clinic, Jacksonville, Florida, USA.
  • Division of Hematology, Mayo Clinic, Scottsdale, Arizona, USA.
  • Section of Hematology-Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA.
  • Department of Medicine, University of Chicago, Chicago, Illinois, USA.
  • Department of Pharmacy, University of Chicago, Chicago, Illinois, USA.

ORCID-Profile: Naseema Gangat, Kristen McCullough, Aref Al-Kali, Kebede H Begna, Michelle Elliott, Abhishek Mangaonkar, Antoine N Saliba, Mehrdad Hefazi Torghabeh, Mark R Litzow, Mithun Shah, Mrinal M Patnaik, Animesh Pardanani, Talha Badar, Hemant Murthy, Cecilia Arana Yi, Anand A Patel, Alexandre Bazinet, Jayastu Senapati, Alex Bataller, Courtney DiNardo, Tapan Kadia, Ayalew Tefferi

Zitieren

APA

Gangat, N., Elbeih, A., Ghosoun, N., McCullough, K., Aperna, F., Johnson, I. M., Abdelmagid, M., Al-Kali, A., Alkhateeb, H. B., Begna, K. H., Elliott, M., Mangaonkar, A., Matin, A., Saliba, A. N., Hefazi Torghabeh, M., Litzow, M. R., Hogan, W., Shah, M., Patnaik, M. M., …, & Tefferi, A. (2025). Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent. American Journal of Hematology, 100(2), 260-271. https://doi.org/10.1002/ajh.27564

Vancouver

Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, et al. Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent. American Journal of Hematology. 2025;100(2):260-271. doi:10.1002/ajh.27564

BibTeX
@article{Gangat2025,
  author = {Gangat, Naseema and Elbeih, Azeem and Ghosoun, Nour and McCullough, Kristen and Aperna, Fnu and Johnson, Isla M and Abdelmagid, Maymona and Al-Kali, Aref and Alkhateeb, Hassan B and Begna, Kebede H and Elliott, Michelle and Mangaonkar, Abhishek and Matin, Aasiya and Saliba, Antoine N and Hefazi Torghabeh, Mehrdad and Litzow, Mark R and Hogan, William and Shah, Mithun and Patnaik, Mrinal M and Pardanani, Animesh and Badar, Talha and Murthy, Hemant and Foran, James and Palmer, Jeanne and Sproat, Lisa and Khera, Nandita and Arana Yi, Cecilia and Yates, Samuel and Sneider, Abigail and Dworkin, Emily and Patel, Anand A and Bazinet, Alexandre and Senapati, Jayastu and Bataller, Alex and DiNardo, Courtney and Kadia, Tapan and Tefferi, Ayalew},
  title = {Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent},
  journal = {American Journal of Hematology},
  year = {2025},
  volume = {100},
  number = {2},
  pages = {260--271},
  doi = {10.1002/ajh.27564}
}
Kostenlos starten →